NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Opinion|Videos|December 11, 2024

Defining LR-MDS: Initial Patient Presentation and Updates in MDS Risk.

Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD

Panelists discuss how the initial presentation of lower-risk myelodysplastic syndromes (LR-MDS) involves anemia and other cytopenias, with updates on MDS risk assessment using prognostic scoring systems like such as IPSS-R and IPSS-M to guide treatment decisions.

Episodes in this series

EP. 1 Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes.

EP. 1 Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes.

EP. 2 Defining LR-MDS: Initial Patient Presentation and Updates in MDS Risk.

EP. 2 Defining LR-MDS: Initial Patient Presentation and Updates in MDS Risk.

EP. 3 Frontline Treatment Options for LR-MDS Beyond ESAs

EP. 3 Frontline Treatment Options for LR-MDS Beyond ESAs

EP. 4 Overview of Frontline Luspatercept in LR-MDS

EP. 4 Overview of Frontline Luspatercept in LR-MDS

EP. 5 Academic Perspectives: Patient Populations for Frontline Luspatercept in LR-MDS

EP. 5 Academic Perspectives: Patient Populations for Frontline Luspatercept in LR-MDS

EP. 6 Emerging Insights and Perspectives From COMMANDS (Luspatercept in LR-MDS)

EP. 6 Emerging Insights and Perspectives From COMMANDS (Luspatercept in LR-MDS)

EP. 7 The Impact of Mutational Burden on Responses With Frontline Luspatercept in LR-MDS

EP. 7 The Impact of Mutational Burden on Responses With Frontline Luspatercept in LR-MDS

EP. 8 Factors that Influence Treatment Choices and Goals in Frontline LR-MDS

EP. 8 Factors that Influence Treatment Choices and Goals in Frontline LR-MDS

EP. 9 Dosing Strategies for Frontline luspatercept in LR-MDS

EP. 9 Dosing Strategies for Frontline luspatercept in LR-MDS

EP. 10 Novel Updates in Second-line Therapies for LR-MDS

EP. 10 Novel Updates in Second-line Therapies for LR-MDS

EP. 11 Sequencing Therapies in LR-MDS

EP. 11 Sequencing Therapies in LR-MDS

EP. 12 Academic Perspectives for LR-MDS Treatment in the Community

EP. 12 Academic Perspectives for LR-MDS Treatment in the Community

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

Summary and Key Takeaways for First-Line EGFR-Mutant NSCLC With Brain Metastases

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

Evolving Treatment Landscape and Future Directions n First-Line EGFR-Mutant NSCLC

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

Subcutaneous Amivantamab and Q4W Dosing for First-Line EGFR-Mutant NSCLC

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

Safety Profiles and Proactive Therapy Management of First-Line Regimens in EGFR-Mutant NSCLC

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

CNS Surveillance and Long-Term Management in EGFR-Mutant NSCLC With Brain Metastases

ByEstelamari Rodriguez, MD, MPH

May 28th 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society

Seth A. Wander, MD, PhD; Kamel Abou Hussein, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Alison K. Conlin, MD; Neil M. Iyengar, MD

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

June 8, 2026

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Yan Ji, MD; Neil M. Iyengar, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH

Iowa Oncology Society

Iowa Oncology Society

2 Sessions are Available!

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Seth A. Wander, MD, PhD; Yang Liu, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Yelda Nouri, MD; Sara Nunnery, MD, MSCI

Louisiana Oncology Society

Louisiana Oncology Society

2 Sessions are Available!

Missouri Oncology Society

Missouri Oncology Society

2 Sessions are Available!

New Mexico Society of Clinical Oncology

New Mexico Society of Clinical Oncology

2 Sessions are Available!

25th Annual International Congress on the Future of Breast Cancer® East

In-Person + Virtual Event

25th Annual International Congress on the Future of Breast Cancer® East

July 10-11, 2026

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

25th Annual International Congress on the Future of Breast Cancer® West

In-Person Event

25th Annual International Congress on the Future of Breast Cancer® West

July 17-18, 2026

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

1 Session is Available!

Indiana Oncology Society

Indiana Oncology Society

2 Sessions are Available!

Rhode Island Oncology Society

Rhode Island Oncology Society

3 Sessions are Available!

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma

Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC

ASCO 2026 GU Cancer Highlights: Beyond the LBAs

FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer

Gedatolisib Combinations Double PFS in PIK3CA-Mutant Breast Cancer